The study on the impacts of REACH authorisation indicates that the system is achieving its objectives. The authorisation system is progressively promoting substitution of substances of very high concern (SVHCs) by available alternatives and reducing risks associated with the use of SVHCs.
The main benefits of authorisation:
(1) REACH is one of the main drivers for substitution of SVHCs, from as early as the candidate listing stage
(2) Companies are improving risk management measures and operating conditions when substitution of SVHCs is not possible
The study analysed the changes in the market for SVHCs and the markets for their alternatives but found no clear indications of changes. The study could not fully quantify the costs of the overall authorisation process. However, it did provide an estimation of costs related to the process of application for authorisation, both for authorities and for companies.